focus -WSS

focus

author：entertainment 2025-09-29 22:46:44 - browse：28176

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： UPS workers' union leader explains what's at stake as strike edges closer

WSS

3 questions for the future of Biden's cancer moonshot

How corporate America is slashing DEI workers amid backlash to diversity programs

Rare Northern Lights show in US this week: Where and how to see it

Chemotherapy drug shortage eases slightly but still widespread

Why Titanic fascinates society, still drawing tours to the wreckage

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

What does generative AI mean for health care? We asked experts

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Medical leaders decry Supreme Court decision on affirmative action

The future of health care in the House

State Dept. review finds Biden bears some blame for Afghanistan failures

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

After affirmative action ruling, medical educators look to 'holistic review'

AI can decode, harness the power of the humane immune system

Guidelines to prevent youth baseball injuries need more muscle

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Wikipedia

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

VC firm General Catalyst wants to buy a health system

Phenylephrine and the overlooked value of the placebo effect

Rare Northern Lights show in US this week: Where and how to see it

Rare Northern Lights show in US this week: Where and how to see it

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

hotspot

entertainment

focus

focus